Betbeder Didier is professor of physiology at the University of Artois and Lille, France. He has 20 years experience in mucosal vaccine using colloids, ranging from basic research to clinical studies. Working with WHO he obtained his PhD in 1988 on drug targeting to treat sleeping sickness, before spending 2 years as a post-doctoral fellow at the University of Warwick (England). He joined Biovector Therapeutics (France) as Research director to develop nasal flu vaccine using nanoparticles as adjuvant. He has been a Professor at the University of Artois and Lille since 2001 and has over 60 international publications and 21 patents to his name. He is board member SFNano since 2013 and was president of the French control release society (GTRV) from 2004-08.


Nanoparticles can be used to deliver antigens to immune cells, therefore increasing their immunogenicity. A better knowledge of their mechanisms of interaction with cells and the biological fluids is necessary to fully understand their potential as delivery systems of antigens. Most of nanotechnologies-antigens complex to formulate proteins implies surfactant, organic solvents, temperature conditions all these parameters are generally considered to be deleterious from proteins and is a limitation for further medical applications. To overcome these inconveniences, we developed a new concept based on porous nanoparticles to obtain protein loading in water without requiring any organic solvent or surfactant. These nanoparticles made from starch hydrolysate (maltodextrin) can be used alone or associated with lipids. Proteins loaded are efficiently rotected from proteolysis and antigens are highly delivered within cells and when administered intra-nasally or sub-linguallly this delivery vehicle was capable of eliciting humoral, cellular and mucosal immunity without the use of adjuvant. This lecture will give an overview of the mechanisms implied using nanoparticles to deliver antigens to the immune cells using the nasal route of administration.